

Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014

LEXINGTON, Mass., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2013 financial results on Thursday, February 20, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. Eastern Standard Time to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427 as well as its partnered programs, including Erivedge® (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2013.

To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 9:00 A.M. EST. The conference ID number is 63234866. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Saturday, March 1, 2014. To access the replay, please call (855) 859-2056 from the United States or (404) 537-3406 from other locations and reference the conference ID number 63234866.

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers. Curis is seeking to further the development of its pipeline of proprietary targeted cancer drug candidates, including CUDC-907, a dual HDAC and PI3K inhibitor, and CUDC-427, a small molecule antagonist of IAP proteins. Curis is also engaged in a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. Curis-discovered HSP90 inhibitor, Debio 0932 is being studied in patients with advanced lung and kidney cancers by partner Debiopharm. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information:

Michael P. Gray

Chief Business & Chief Financial Officer

Curis, Inc.

617-503-6632

mgray@curis.com

<https://investors.curis.com/Curis-to-Release-Fourth-Quarter-and-Year-End-2013-Financial-Results-and-Hold-Conference-Call-on-February-20-2014>